Approval Year
| Substance Class |
Concept
|
| Record UNII |
7EM2VXC85Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
810021
Created by
admin on Wed Apr 02 11:01:17 GMT 2025 , Edited by admin on Wed Apr 02 11:01:17 GMT 2025
|
||
|
FDA ORPHAN DRUG |
784020
Created by
admin on Wed Apr 02 11:01:17 GMT 2025 , Edited by admin on Wed Apr 02 11:01:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C185861
Created by
admin on Wed Apr 02 11:01:17 GMT 2025 , Edited by admin on Wed Apr 02 11:01:17 GMT 2025
|
PRIMARY | |||
|
7EM2VXC85Q
Created by
admin on Wed Apr 02 11:01:17 GMT 2025 , Edited by admin on Wed Apr 02 11:01:17 GMT 2025
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Upon binding to Claudin18.2-expressing tumor cells, NBL-015 mediates antibody-dependent
cellular toxicity (ADCC) in the presence of NK cells
|
This is a non-substance concept